港股异动 | 拨康视云-B(02592)现涨超4% 附属将与美国FDA讨论CBT-004研发事项

智通财经
Dec 10, 2025

智通财经APP获悉,拨康视云-B(02592)现涨超4%,截至发稿,涨4.13%,报8.58港元,成交额1182.43万港元。

消息面上,拨康视云此前公告,本公司于美国加利福尼亚州注册成立的全资附属公司Cloudbreak USA排定于2025年12月10日与美国食品及药物管理局正式举行第2期临床试验后会议,该会议涉及集团临床阶段候选药物 CBT-004。此次第2期临床试验后会议是CBT-004研发进程中一个重要的里程碑,用于讨论CBT-004研发进程中潜在的第三阶段临床试验开发以及新药申请的相关要求。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10